Your browser doesn't support javascript.
loading
Impaired immune response to COVID-19 vaccination in patients with B-cell malignancies after CD19 CAR T-cell therapy.
Dahiya, Saurabh; Luetkens, Tim; Lutfi, Forat; Avila, Stephanie; Iraguha, Thierry; Margiotta, Philip; Hankey, Kim G; Lesho, Patricia; Law, Jennie Y; Lee, Seung T; Baddley, John; Kocoglu, Mehmet; Yared, Jean A; Hardy, Nancy M; Rapoport, Aaron P; Atanackovic, Djordje.
Afiliación
  • Dahiya S; Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine and University of Maryland Medical System, Baltimore, MD; and.
  • Luetkens T; Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine and University of Maryland Medical System, Baltimore, MD; and.
  • Lutfi F; Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine and University of Maryland Medical System, Baltimore, MD; and.
  • Avila S; Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine and University of Maryland Medical System, Baltimore, MD; and.
  • Iraguha T; Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine and University of Maryland Medical System, Baltimore, MD; and.
  • Margiotta P; Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine and University of Maryland Medical System, Baltimore, MD; and.
  • Hankey KG; Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine and University of Maryland Medical System, Baltimore, MD; and.
  • Lesho P; Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine and University of Maryland Medical System, Baltimore, MD; and.
  • Law JY; Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine and University of Maryland Medical System, Baltimore, MD; and.
  • Lee ST; Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine and University of Maryland Medical System, Baltimore, MD; and.
  • Baddley J; Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine and University of Maryland Medical System, Baltimore, MD; and.
  • Kocoglu M; Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD.
  • Yared JA; Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine and University of Maryland Medical System, Baltimore, MD; and.
  • Hardy NM; Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine and University of Maryland Medical System, Baltimore, MD; and.
  • Rapoport AP; Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine and University of Maryland Medical System, Baltimore, MD; and.
  • Atanackovic D; Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine and University of Maryland Medical System, Baltimore, MD; and.
Blood Adv ; 6(2): 686-689, 2022 01 25.
Article en En | MEDLINE | ID: mdl-34941995
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas contra la COVID-19 / COVID-19 Límite: Humans Idioma: En Revista: Blood Adv Año: 2022 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas contra la COVID-19 / COVID-19 Límite: Humans Idioma: En Revista: Blood Adv Año: 2022 Tipo del documento: Article Pais de publicación: Estados Unidos